Steffen Kahlert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steffen Kahlert has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Michael Untch
3 shared publicationsA. Strauss
1 shared publication- Andrea Vodermaier1 shared publication
Annette Lebeau
1 shared publication- Birgit Wackwitz
18Novartis Pharma GmbH, Nuremberg, Germany
1 shared publication - Christopher Wolf
Medical Center Ulm, Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 20 September 2018
- Published by Springer Nature in BMC Medical Genomics
- Vol. 11 (1) , 80
Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers
The transition from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) is an important step during breast carcinogenesis. Understanding its molecular changes may help to identify high-risk DCIS that progress to IBC. Here, we describe a transcriptomic profiling analysis of matched formalin-fixed and paraffin-embedded (FFPE) DCIS and IBC components of individual breast tumours, containing both tumour compartments. The study was performed to validate progression-associated transcripts detected in an earlier gene profiling project using fresh frozen breast cancer tissue. In addition, FFPE tissues from patients with pure DCIS (pDCIS) were analysed to identify candidate transcripts characterizing DCIS with a high or low risk of progressing to IBC. Fifteen laser microdissected pairs of DCIS and IBC were profiled by Illumina DASL technology and used for expression validation by qPCR. Differential expression was independently validated using further 25 laser microdissected DCIS/IBC sample pairs. Additionally, laser microdissected epithelial cells from 31 pDCIS were investigated for expression of candidate transcripts using qPCR. Multiple statistical calculation methods revealed 1784 mRNAs which are differentially expressed between DCIS and IBC (P < 0.05), of which 124 have also been identified in the gene profiling project using fresh frozen breast cancer tissue. Nine mRNAs that had been selected from the gene list obtained using fresh frozen tissues by applying pathway and network analysis (MMP11, GREM1, PLEKHC1, SULF1, THBS2, CSPG2, COL10A1, COL11A1, KRT14) were investigated in tissues from the same 15 microdissected specimens and the 25 independent tissue samples by qPCR. All selected transcripts were also detected in tumour cells from pDCIS. Expression of MMP11 and COL10A1 increased significantly from pDCIS to DCIS of DCIS/IBC mixed tumours. We confirm differential expression of progression-associated transcripts in FFPE breast cancer samples which might mediate the transition from DCIS to IBC. MMP11 and COL10A1 may characterize pure DCIS with a high risk developing IDC.
- 20 September 2018
- Published by Springer Nature in BMC Medical Genomics
- Vol. 11 (1) , 80
Open AccessProgression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers
The transition from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) is an important step during breast carcinogenesis. Understanding its molecular changes may help to identify high-risk DCIS that progress to IBC. Here, we describe a transcriptomic profiling analysis of matched formalin-fixed and paraffin-embedded (FFPE) DCIS and IBC components of individual breast tumours, containing both tumour compartments. The study was performed to validate progression-associated transcripts detected in an earlier gene profiling project using fresh frozen breast cancer tissue. In addition, FFPE tissues from patients with pure DCIS (pDCIS) were analysed to identify candidate transcripts characterizing DCIS with a high or low risk of progressing to IBC. Fifteen laser microdissected pairs of DCIS and IBC were profiled by Illumina DASL technology and used for expression validation by qPCR. Differential expression was independently validated using further 25 laser microdissected DCIS/IBC sample pairs. Additionally, laser microdissected epithelial cells from 31 pDCIS were investigated for expression of candidate transcripts using qPCR. Multiple statistical calculation methods revealed 1784 mRNAs which are differentially expressed between DCIS and IBC (P < 0.05), of which 124 have also been identified in the gene profiling project using fresh frozen breast cancer tissue. Nine mRNAs that had been selected from the gene list obtained using fresh frozen tissues by applying pathway and network analysis (MMP11, GREM1, PLEKHC1, SULF1, THBS2, CSPG2, COL10A1, COL11A1, KRT14) were investigated in tissues from the same 15 microdissected specimens and the 25 independent tissue samples by qPCR. All selected transcripts were also detected in tumour cells from pDCIS. Expression of MMP11 and COL10A1 increased significantly from pDCIS to DCIS of DCIS/IBC mixed tumours. We confirm differential expression of progression-associated transcripts in FFPE breast cancer samples which might mediate the transition from DCIS to IBC. MMP11 and COL10A1 may characterize pure DCIS with a high risk developing IDC.
- Open Access
- 5 February 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 66
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data. Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm. No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.
- 5 February 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 66
Open AccessFemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data. Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm. No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.
- 26 July 2007
- Vol. 27, 1929-32
The risk of non-sentinel metastases in primary breast cancer.
Sentinel node biopsy (SNB) has been established as standard of surgical care in primary breast cancer. If the sentinel node (SN) is negative, axillary dissection (ALND) is not necessary, but if the SN is positive ALND is warranted. This analysis evaluated associated risk factors for non-sentinel metastases in the case of a positive SN. A retrospective analysis of all SNB performed between 10/1999 and 07/2005 was carried out. A total of 406 patients were included: 214 patients (51%) had SNB with ALND while 197 patients (49%) had SNB only. In 41 of 109 nodal-positive patients, the SN was the only nodal metastasis. In the multivariate analysis, the number of positive SN and the presence of lymphatic vessel infiltration were significant risk factors for additional non-sentinel metastases (p = 0.05 and 0.047, respectively). The risk for non-sentinel metastases was 25.9% without and 59.2% with these risk factors, respectively. If the SN is positive, ALND remains obligatory.
- 26 July 2007
- Vol. 27, 1929-32
The risk of non-sentinel metastases in primary breast cancer.
Sentinel node biopsy (SNB) has been established as standard of surgical care in primary breast cancer. If the sentinel node (SN) is negative, axillary dissection (ALND) is not necessary, but if the SN is positive ALND is warranted. This analysis evaluated associated risk factors for non-sentinel metastases in the case of a positive SN. A retrospective analysis of all SNB performed between 10/1999 and 07/2005 was carried out. A total of 406 patients were included: 214 patients (51%) had SNB with ALND while 197 patients (49%) had SNB only. In 41 of 109 nodal-positive patients, the SN was the only nodal metastasis. In the multivariate analysis, the number of positive SN and the presence of lymphatic vessel infiltration were significant risk factors for additional non-sentinel metastases (p = 0.05 and 0.047, respectively). The risk for non-sentinel metastases was 25.9% without and 59.2% with these risk factors, respectively. If the SN is positive, ALND remains obligatory.
- 26 July 2007
- Vol. 27, 1963-8
Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
- 26 July 2007
- Vol. 27, 1963-8
Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
- 3 June 2004
- Published by Georg Thieme Verlag KG in Zentralblatt Fur Gynakologie
- Vol. 126 (03) , 159-166
Behandlung des Mammakarzinoms in der Schwangerschaft - Erfahrungen aus der Universitätsfrauenklinik Großhadern und Internationale Datenlage
Das Mammakarzinom ist mit einer Häufigkeit von einem Fall auf 3 000-10 000 Schwangerschaften das zweithäufigste Malignom in der Schwangerschaft nach dem Zervixkarzinom. Der Verlauf von 12 Patientinnen mit schwangerschafts-assoziiertem Mammakarzinom aus der Universitätsfrauenklinik Großhadern (Erstdiagnose zwischen 1990 bis 2002) wurde analysiert und in Hinblick auf die internationale Literatur diskutiert. Acht Frauen wurden während der Schwangerschaft operiert (vier radikal, vier brusterhaltend), vier noch während der Gravidität mit CMF chemotherapiert (1 bis 4 Zyklen). Drei weitere Patientinnen wurden im Wochenbett behandelt. Die Tumorstadien waren ungünstig (> 2 cm: 10/11; N pos.: 8/11; G3: 7/11; ER/PR neg.: 5/11). Eine Patientin mit metastasiertem Karzinom konnte nur palliativ betreut werden und starb 1 Woche nach Diagnosestellung und eiliger Sectioentbindung in der 31. SSW. Die mediane Überlebenszeit aller Patientinnen betrug 41 Monate, wobei sechs Frauen bisher verstorben sind. Eine Schwangerschaft wurde in der 20. SSW durch Abruptio beendet. Ein intrauteriner Fruchttod in der 24. SSW trat bei einer Patientin ohne Chemotherapie auf. Von den anderen sechs Schwangerschaften wurden vier durch Sectio beendet, zwei Kinder wurden spontan nach Einleitung geboren. Ein Kind verstarb postnatal mit Trisomie 18. Die fünf gesunden Kinder (aktuell 3 bis 12 Jahre) haben sich bisher normal entwickelt. Die Fälle zeigen, welche Herausforderung die Therapie eines schwangerschafts-assoziierten Mammakarzinoms darstellt, aber auch die in dieser Situation gegebenen Möglichkeiten. Größtes Augenmerk sollte auf die psychologische Betreuung der Frau und ihrer Familie gelegt werden. With an incidence of 1 case in 3 000 to 10 000 pregnancies, breast cancer is the second common pregnancy associated malignancy besides cervical cancer. An analysis of 12 patients with pregnancy associated breast cancer, treated at the University Department of OB/GYN Grosshadern, and a review of the international literature is presented. Eight women underwent surgery during pregnancy (four radical mastectomies, four breast conserving procedures), four received CMF-chemotherapy during pregnancy (1 to 4 cycles). Three other patients were treated post partum. The tumor stages were advanced (> 2 cm: 10/11; N pos.: 8/11; G3: 7/11; ER/PR neg.: 5/11). One patient with metastatic breast cancer received palliative care only and died 1 week after diagnosis and emergency caesarean section in the 31st gestational week. Median overall survival was 41 months with six patients dead of breast cancer. One pregnancy was terminated in the 20th week of gestation by legal abortion, another because of intrauterine death in the 24th gestational week. Of the other six pregnancies, four were terminated by elective caesarean section and two by induced vaginal delivery. One child died with trisomy 18 shortly after birth. The five healthy children (now aged 3 to 12 years) showed normal development up to now. The cases show the challenge and the opportunities associated with therapy of pregnancy associated breast cancer. Utmost attention should be turned to the psychological support of the woman and her family.
- 3 June 2004
- Published by Georg Thieme Verlag KG in Zentralblatt Fur Gynakologie
- Vol. 126 (03) , 159-166
Behandlung des Mammakarzinoms in der Schwangerschaft - Erfahrungen aus der Universitätsfrauenklinik Großhadern und Internationale Datenlage
Das Mammakarzinom ist mit einer Häufigkeit von einem Fall auf 3 000-10 000 Schwangerschaften das zweithäufigste Malignom in der Schwangerschaft nach dem Zervixkarzinom. Der Verlauf von 12 Patientinnen mit schwangerschafts-assoziiertem Mammakarzinom aus der Universitätsfrauenklinik Großhadern (Erstdiagnose zwischen 1990 bis 2002) wurde analysiert und in Hinblick auf die internationale Literatur diskutiert. Acht Frauen wurden während der Schwangerschaft operiert (vier radikal, vier brusterhaltend), vier noch während der Gravidität mit CMF chemotherapiert (1 bis 4 Zyklen). Drei weitere Patientinnen wurden im Wochenbett behandelt. Die Tumorstadien waren ungünstig (> 2 cm: 10/11; N pos.: 8/11; G3: 7/11; ER/PR neg.: 5/11). Eine Patientin mit metastasiertem Karzinom konnte nur palliativ betreut werden und starb 1 Woche nach Diagnosestellung und eiliger Sectioentbindung in der 31. SSW. Die mediane Überlebenszeit aller Patientinnen betrug 41 Monate, wobei sechs Frauen bisher verstorben sind. Eine Schwangerschaft wurde in der 20. SSW durch Abruptio beendet. Ein intrauteriner Fruchttod in der 24. SSW trat bei einer Patientin ohne Chemotherapie auf. Von den anderen sechs Schwangerschaften wurden vier durch Sectio beendet, zwei Kinder wurden spontan nach Einleitung geboren. Ein Kind verstarb postnatal mit Trisomie 18. Die fünf gesunden Kinder (aktuell 3 bis 12 Jahre) haben sich bisher normal entwickelt. Die Fälle zeigen, welche Herausforderung die Therapie eines schwangerschafts-assoziierten Mammakarzinoms darstellt, aber auch die in dieser Situation gegebenen Möglichkeiten. Größtes Augenmerk sollte auf die psychologische Betreuung der Frau und ihrer Familie gelegt werden. With an incidence of 1 case in 3 000 to 10 000 pregnancies, breast cancer is the second common pregnancy associated malignancy besides cervical cancer. An analysis of 12 patients with pregnancy associated breast cancer, treated at the University Department of OB/GYN Grosshadern, and a review of the international literature is presented. Eight women underwent surgery during pregnancy (four radical mastectomies, four breast conserving procedures), four received CMF-chemotherapy during pregnancy (1 to 4 cycles). Three other patients were treated post partum. The tumor stages were advanced (> 2 cm: 10/11; N pos.: 8/11; G3: 7/11; ER/PR neg.: 5/11). One patient with metastatic breast cancer received palliative care only and died 1 week after diagnosis and emergency caesarean section in the 31st gestational week. Median overall survival was 41 months with six patients dead of breast cancer. One pregnancy was terminated in the 20th week of gestation by legal abortion, another because of intrauterine death in the 24th gestational week. Of the other six pregnancies, four were terminated by elective caesarean section and two by induced vaginal delivery. One child died with trisomy 18 shortly after birth. The five healthy children (now aged 3 to 12 years) showed normal development up to now. The cases show the challenge and the opportunities associated with therapy of pregnancy associated breast cancer. Utmost attention should be turned to the psychological support of the woman and her family.
- 1 March 2004
- Vol. 98 (2) , 127-33
[Shared decision-making in primary breast cancer].
Following an overall view of the emotional situation of primary breast cancer patients and of studies exploring shared decision making in this setting we present the results of qualitative analyses about breaking bad news situations and interviews with this group of patients and describe both methods for implementing shared decision making in the treatment of primary breast cancer and an evaluation study. The main result was that most patients showed a lack of information about breast cancer and its therapy, which led to uncertainty. Another source of uncertainty was the lack of preoperative punch biopsy. Due to the so-called "diagnostic shock" patients felt under pressure to make a quick decision over their treatment. This perceived pressure can be effectively countered by a shared decision making approach. To investigate the options in breast cancer therapy, decision aids for diagnostic and therapeutic options have been developed focusing on the following treatment modalities: 1. breast conserving therapy and radiation versus radical mastectomy 2. chemotherapy plus endocrine therapy versus endocrine therapy alone 3. preoperative versus postoperative chemotherapy. The decision instruments in question were tested in N = 35 breast cancer patients and N = 36 nurses as a control group. The results of a questionnaire survey among both these groups revealed a very positive appraisal of the decision aids. Implementation in daily routine was favoured.
- 1 March 2004
- Vol. 98 (2) , 127-33
[Shared decision-making in primary breast cancer].
Following an overall view of the emotional situation of primary breast cancer patients and of studies exploring shared decision making in this setting we present the results of qualitative analyses about breaking bad news situations and interviews with this group of patients and describe both methods for implementing shared decision making in the treatment of primary breast cancer and an evaluation study. The main result was that most patients showed a lack of information about breast cancer and its therapy, which led to uncertainty. Another source of uncertainty was the lack of preoperative punch biopsy. Due to the so-called "diagnostic shock" patients felt under pressure to make a quick decision over their treatment. This perceived pressure can be effectively countered by a shared decision making approach. To investigate the options in breast cancer therapy, decision aids for diagnostic and therapeutic options have been developed focusing on the following treatment modalities: 1. breast conserving therapy and radiation versus radical mastectomy 2. chemotherapy plus endocrine therapy versus endocrine therapy alone 3. preoperative versus postoperative chemotherapy. The decision instruments in question were tested in N = 35 breast cancer patients and N = 36 nurses as a control group. The results of a questionnaire survey among both these groups revealed a very positive appraisal of the decision aids. Implementation in daily routine was favoured.